1
|
Increased Migratory and Activation Cell Markers of Peripheral Blood Lymphocytes in an Experimental Model of Nephrotic Syndrome. Mediators Inflamm 2015; 2015:209764. [PMID: 26063968 PMCID: PMC4439504 DOI: 10.1155/2015/209764] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2015] [Revised: 04/18/2015] [Accepted: 04/19/2015] [Indexed: 12/11/2022] Open
Abstract
The present study aimed to evaluate the expression of CD80 and CD18 in subpopulations of peripheral blood leukocytes and oxidative kidney damage in rats with nephrotic syndrome (NS) induced by doxorubicin (Dox) in comparison to control animals at different time points. Male adult Wistar rats were submitted to 24-hour urine and blood collection for biochemical and immunological analysis at 7, 14, 21, and 28 days after Dox injection. After euthanasia, the kidneys were removed for histological analysis and the evaluation of oxidative stress. The phenotypic characterization of leukocytes was performed using flow cytometry. Dox-injected animals exhibited increased CD18 expression in cytotoxic T lymphocytes, NK cells, and monocytes and high CD80 expression in monocytes. Kidney oxidative damage was positively correlated with CD80 expression in monocytes and serum levels of creatinine. These results suggest that phagocytic and cytotoxic cells are preferentially recruited to the tissue injury site, which may contribute to kidney dysfunction in this animal model of NS. The blockade of integrin and costimulatory molecules may provide new therapeutic opportunities for NS.
Collapse
|
2
|
Moreno-Manzano V, Mampaso F, Sepúlveda-Muñoz JC, Alique M, Chen S, Ziyadeh FN, Iglesias-de la Cruz MC, Rodríguez J, Nieto E, Orellana JM, Reyes P, Arribas I, Xu Q, Kitamura M, Lucio Cazana FJ. Retinoids as a potential treatment for experimental puromycin-induced nephrosis. Br J Pharmacol 2003; 139:823-31. [PMID: 12813006 PMCID: PMC1573906 DOI: 10.1038/sj.bjp.0705311] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
1 Puromycin aminonucleoside (PAN)-induced nephrosis is a model of human minimal change disease. In rats, PAN induces nephrotic-range proteinuria, renal epithelial cell (podocyte) damage, infiltration of mononuclear leukocytes, and apoptosis of several renal cell types. 2 Retinoic acid (RA) modulates a wide range of biological processes, such as inflammation and apoptosis. Since renal damage by PAN is characterized by inflammatory infiltration and epithelial cell death, the effect of treatment with all-trans RA (tRA) was examined in the PAN nephrosis model and in the cultured differentiated podocyte. 3 Treatment with tRA 4 days after PAN injection did not inhibit the proteinuria peak but reversed it significantly. However, treatment with tRA both before and 2 days after the injection of PAN protected the glomerular epithelial cells, diminishing the cellular edema and diffuseness of the foot process effacement. Preservation of the podocyte architecture correlated with the inhibition of proteinuria. The anti-inflammatory effect of tRA was evidenced by the inhibition of PAN-induced interstitial mononuclear cell infiltration and the decreased renal expression of two molecules involved in monocyte infiltration: fibronectin and monocyte chemoattractant protein-1. TUNEL assays showed that tRA inhibited the PAN-induced apoptosis of cultured differentiated mouse podocytes. 4 We conclude that tRA treatment may prevent proteinuria by protecting the podocytes from injury and diminishing the interstitial mononuclear infiltrate in the model of PAN nephrosis. Retinoids are a potential new treatment for kidney diseases characterized by proteinuria and mononuclear cell infiltration.
Collapse
Affiliation(s)
- V Moreno-Manzano
- Department of Physiology, University of Alcalá, E-28871 Alcalá de Henares, Madrid, Spain
| | - F Mampaso
- Department of Pathology, Hospital Ramón y Cajal, University of Alcalá, Madrid, Spain
| | - J C Sepúlveda-Muñoz
- Department of Physiology, University of Alcalá, E-28871 Alcalá de Henares, Madrid, Spain
| | - M Alique
- Department of Physiology, University of Alcalá, E-28871 Alcalá de Henares, Madrid, Spain
| | - S Chen
- Department of Medicine, Renal-Electrolyte and Hypertension Division, Penn Center for the Molecular Studies of Kidney Diseases, University of Pennsylvania, Philadelphia, PA, U.S.A
| | - F N Ziyadeh
- Department of Medicine, Renal-Electrolyte and Hypertension Division, Penn Center for the Molecular Studies of Kidney Diseases, University of Pennsylvania, Philadelphia, PA, U.S.A
| | - M C Iglesias-de la Cruz
- Department of Medicine, Renal-Electrolyte and Hypertension Division, Penn Center for the Molecular Studies of Kidney Diseases, University of Pennsylvania, Philadelphia, PA, U.S.A
| | - J Rodríguez
- Department of Physiology, University of Alcalá, E-28871 Alcalá de Henares, Madrid, Spain
| | - E Nieto
- Department of Pathology, Hospital Ramón y Cajal, University of Alcalá, Madrid, Spain
| | - J M Orellana
- Department of Physiology, University of Alcalá, E-28871 Alcalá de Henares, Madrid, Spain
| | - P Reyes
- Department of Physiology, University of Alcalá, E-28871 Alcalá de Henares, Madrid, Spain
| | - I Arribas
- Department of Physiology, University of Alcalá, E-28871 Alcalá de Henares, Madrid, Spain
| | - Q Xu
- Department of Medicine, University College Medical School, University College London, Jules Thorn Institute, Middlesex Hospital, Mortimer Street. London W1 T 3AA
| | - M Kitamura
- Institute of Clinical Medicine and Research, Jikei University School of Medicine, Japan
| | - F J Lucio Cazana
- Department of Physiology, University of Alcalá, E-28871 Alcalá de Henares, Madrid, Spain
- Author for correspondence:
| |
Collapse
|
3
|
Tofovic SP, Kost CK, Jackson EK, Bastacky SI. Long-term caffeine consumption exacerbates renal failure in obese, diabetic, ZSF1 (fa-fa(cp)) rats. Kidney Int 2002; 61:1433-44. [PMID: 11918750 DOI: 10.1046/j.1523-1755.2002.00278.x] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Our preliminary studies indicate that chronic caffeine consumption has adverse renal effects in nephropathy associated with high blood pressure and insulin resistance. The purpose of this study was to investigate the effects of early (beginning at 8 weeks of age) and long-term (30 weeks) caffeine treatment (0.1% solution) on renal function and structure in obese, diabetic ZSF1 rats. METHODS Metabolic and renal function measurements were performed at six-week intervals and in a subset of animals (N = 6 per group) heart rate (HR) and mean arterial blood pressure (MABP) were monitored by a radiotelemetric technique. At the end of the study acute, measurements of renal hemodynamics and excretory function were conducted in anesthetized animals. RESULTS Caffeine produced a very mild increase (4 to 5%) of MABP and HR, but greatly augmented proteinuria (P < 0.001), reduced creatinine clearance (P < 0.05) and had a mixed effect on metabolic status in obese ZSF1 rats. Caffeine significantly reduced body weight, glycosuria, fasting glucose and insulin levels and improved glucose tolerance, had no effect on elevated plasma triglycerides levels and significantly increased plasma cholesterol level (P < 0.001). Acute measurements of renal function revealed increased renal vascular resistance (95.1 +/- 11 vs. 50.7 +/- 2.4 mm Hg/mL/min/g kidney, P < 0.01) and decreased inulin clearance (0.37 +/- 0.11 vs. 0.97 +/- 0.13 mL/min/g kidney, P < 0.002) in caffeine-treated versus control animals, respectively. Caffeine potentiated the development of more severe tubulointerstitial changes (P < 0.05) and increased focal glomerulosclerosis (14.7 +/- 1.7 vs. 6.5 +/- 0.9%, caffeine vs. control, P < 0.002). CONCLUSION The present study provides the first evidence that caffeine (despite improving insulin sensitivity) exacerbates renal failure in obese, diabetic ZSF1 rats. Further mechanistic studies of adverse renal effects of caffeine in chronic renal failure associated with metabolic syndrome are warranted.
Collapse
Affiliation(s)
- Stevan P Tofovic
- Center for Clinical Pharmacology, Department of Medicine, University of Pittsburgh School of Medicine, Pennsylavania 15213-2582, USA.
| | | | | | | |
Collapse
|